# IGM Biosciences Inc. (IGMS)

Source: https://www.quantisnow.com/company/IGMS
Generated: 2026-10-29T20:39:18.753Z

- Ticker: IGMS
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2019
- Website: igmbio.com

## About

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

## Latest IGMS news and filings

- 2025-08-25 13:00 UTC [SEC Form 15-12G filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-igm-biosciences-inc-6177259)
- 2025-08-18 21:52 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-igm-biosciences-inc-6170581)
- 2025-08-18 21:39 UTC [SEC Form 4] [SEC Form 4 filed by Former 10% owner and director Baker Bros. Advisors Lp](https://www.quantisnow.com/insight/sec-form-4-filed-by-former-10-owner-and-director-6170556)
- 2025-08-15 21:01 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-igm-biosciences-inc-6168804)
- 2025-08-15 21:00 UTC [SEC Form 4] [Director Redmile Group, Llc returned 2,964,843 shares to the company (SEC Form 4)](https://www.quantisnow.com/insight/director-redmile-group-llc-returned-2964843-shares-to-the-company-6168790)
- 2025-08-15 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-igm-biosciences-inc-6167642)
- 2025-08-15 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-igm-biosciences-inc-6167640)
- 2025-08-15 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-igm-biosciences-inc-6167639)
- 2025-08-15 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-igm-biosciences-inc-6167638)
- 2025-08-15 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-igm-biosciences-inc-6167636)
- 2025-08-15 00:52 UTC [SEC Form 4] [Director Hambleton Julie returned 2,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-hambleton-julie-returned-2000-shares-to-the-company-closing-6167507)
- 2025-08-14 23:35 UTC [SEC Form 4] [Director Lee Michael Stewart returned 12,712 shares to the company (SEC Form 4)](https://www.quantisnow.com/insight/director-lee-michael-stewart-returned-12712-shares-to-the-company-6167445)
- 2025-08-14 21:28 UTC [SEC Form 4] [Large owner Topsoe Holding A/S returned 10,400,564 shares to the company (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-topsoe-holding-as-returned-10400564-shares-to-the-6167208)
- 2025-08-14 21:26 UTC [SEC Form 4] [Director Topsoe Christina Teng returned 10,464,599 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-topsoe-christina-teng-returned-10464599-shares-to-the-company-6167202)
- 2025-08-14 21:27 UTC [SEC Form 4] [Director Topsoe Jakob Haldor returned 10,492,276 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-topsoe-jakob-haldor-returned-10492276-shares-to-the-company-6167200)
- 2025-08-14 21:25 UTC [SEC Form 4] [Director Thompson Elizabeth H.Z. returned 7,196 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-thompson-elizabeth-hz-returned-7196-shares-to-the-company-6167180)
- 2025-08-14 21:24 UTC [SEC Form 4] [Director Strohl William returned 125,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-strohl-william-returned-125000-shares-to-the-company-closing-6167169)
- 2025-08-14 21:23 UTC [SEC Form 4] [Chief Executive Officer Harler Mary Beth returned 323,680 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-harler-mary-beth-returned-323680-shares-to-6167164)
- 2025-08-14 21:17 UTC [SEC Form 4] [Director Behrens M Kathleen returned 412,535 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-behrens-m-kathleen-returned-412535-shares-to-the-company-6167110)
- 2025-08-14 20:14 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-igm-biosciences-inc-6166275)
- 2025-08-14 20:14 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-igm-biosciences-inc-6166264)
- 2025-08-14 20:13 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-igm-biosciences-inc-6166258)
- 2025-08-14 20:12 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-igm-biosciences-inc-6166248)
- 2025-08-14 20:11 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-igm-biosciences-inc-6166204)
- 2025-08-14 20:10 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-igm-biosciences-inc-6166176)
- 2025-08-14 20:09 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-igm-biosciences-inc-6166146)
- 2025-08-14 20:08 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-igm-biosciences-inc-6166063)
- 2025-08-14 20:05 UTC [SEC Form POS AM filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-igm-biosciences-inc-6166043)
- 2025-08-14 20:06 UTC [SEC Form POS AM filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-igm-biosciences-inc-6166026)
- 2025-08-14 20:06 UTC [SEC Form POS AM filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-igm-biosciences-inc-6166015)
- 2025-08-14 20:06 UTC [SEC Form POS AM filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-igm-biosciences-inc-6166007)
- 2025-08-14 20:05 UTC [SEC Form POS AM filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-igm-biosciences-inc-6165952)
- 2025-08-14 20:03 UTC [SEC Form 8-K] [IGM Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant](https://www.quantisnow.com/insight/igm-biosciences-inc-filed-sec-form-8-k-completion-of-acquisition-6165921)
- 2025-08-14 13:17 UTC [SEC Form 25-NSE filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-igm-biosciences-inc-6164923)
- 2025-08-14 13:06 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-igm-biosciences-inc-6164891)
- 2025-07-31 20:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-igm-biosciences-inc-6140973)
- 2025-07-25 23:06 UTC [SEC Form 4] [CHIEF FINANCIAL OFFICER Tahir Misbah sold $11,126 worth of shares (8,741 units at $1.27), decreasing direct ownership by 5% to 170,061 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-tahir-misbah-sold-11126-worth-of-shares-6133478)
- 2025-07-25 23:03 UTC [SEC Form 4] [Chief Executive Officer Harler Mary Beth sold $18,457 worth of shares (14,501 units at $1.27), decreasing direct ownership by 4% to 323,680 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-harler-mary-beth-sold-18457-worth-of-6133477)
- 2025-07-25 23:01 UTC [SEC Form 4] [CHIEF BUSINESS OFFICER Decker Lisa Lynn sold $5,612 worth of shares (4,409 units at $1.27), decreasing direct ownership by 6% to 68,169 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-officer-decker-lisa-lynn-sold-5612-worth-of-6133476)
- 2025-07-16 20:07 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by IGM Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-igm-biosciences-inc-6122100)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/IGMS
- RSS and alerts for IGMS: https://www.quantisnow.com/docs/rss-feeds.md